Literature DB >> 17397728

Combined preoperative topical atropine sulfate 1% and intracameral nonpreserved epinephrine hydrochloride 1:4000 [corrected] for management of intraoperative floppy-iris syndrome.

Samuel Masket1, Shaleen Belani.   

Abstract

We describe a technique combining preoperative atropine sulfate 1% and intraoperative intracameral epinephrine in a 1:2500 dilution for the management of intraoperative floppy-iris syndrome (IFIS) induced by alpha(1A)-blocking agents such as tamsulosin. Patients on alpha(1A)-blocking agents used topical atropine sulfate 1% 3 times a day for 2 days before surgery. In addition to routine topical mydriatics before surgery, they received intracameral epinephrine diluted 1:2500 with BSS. In 19 of 20 eyes, there were no clinical manifestations of IFIS with this regimen. Stimulation of the iris dilator by a direct-acting sympathomimetic (epinephrine) combined with strong pupiloplegia (atropine) provides powerful synergism. Preoperative identification of patients on alpha(1)-blockers is important as complications can be reduced significantly by using appropriate strategies to deal with this condition. It is also important that patients suffering from benign prostatic hyperplasia do not stop using an alpha(1A)-blocker, especially when preoperative atropine is used, as acute urinary retention may ensue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397728     DOI: 10.1016/j.jcrs.2006.10.059

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  13 in total

1.  Correlation between urological alpha1-AR antagonist medication and changed intraoperative iris behavior.

Authors:  Karin Horvath; Florina Vultur
Journal:  Int Ophthalmol       Date:  2011-01-29       Impact factor: 2.031

2.  Intraoperative floppy iris syndrome and its association with various concurrent medications, bulbus length, patient age and gender.

Authors:  Michael Wahl; Saskia M Tipotsch-Maca; Pia V Vecsei-Marlovits
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-19       Impact factor: 3.117

3.  Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

Authors:  Zuhair K Al-Hussaini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 4.  Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complications.

Authors:  Daniel M Handzel; Sebastian Briesen; Steffen Rausch; Tilman Kälble
Journal:  Dtsch Arztebl Int       Date:  2012-05-25       Impact factor: 5.594

5.  Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

6.  [Managing complications in intraoperative floppy iris syndrome].

Authors:  D M Handzel; S Rausch; T Kälble; S Briesen
Journal:  Ophthalmologe       Date:  2013-04       Impact factor: 1.059

7.  Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.

Authors:  Tiago Santos Prata; Pat-Michael Palmiero; Allison Angelilli; Zaher Sbeity; Carlos Gustavo V De Moraes; Jeffrey M Liebmann; Robert Ritch
Journal:  Ophthalmology       Date:  2009-05       Impact factor: 12.079

8.  Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.

Authors:  Sharon Armarnik; Michael Mimouni; Eli Rosen; Ehud I Assia; Fani Segev
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-09       Impact factor: 3.117

Review 9.  Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.

Authors:  Seanna R Grob; Luis A Gonzalez-Gonzalez; Mary K Daly
Journal:  Clin Ophthalmol       Date:  2014-07-03

Review 10.  Intraoperative Floppy Iris Syndrome Induced by Tamsulosin: The Risk and Preventive Strategies.

Authors:  Mansour Tobaiqy; Waseem Aalam; David Banji; Ekram N Abd Al Haleem
Journal:  Middle East Afr J Ophthalmol       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.